PMID- 34930258
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211224
IS  - 1475-2867 (Print)
IS  - 1475-2867 (Electronic)
IS  - 1475-2867 (Linking)
VI  - 21
IP  - 1
DP  - 2021 Dec 20
TI  - Comprehensive analysis identifies IFI16 as a novel signature associated with 
      overall survival and immune infiltration of skin cutaneous melanoma.
PG  - 694
LID - 10.1186/s12935-021-02409-6 [doi]
LID - 694
AB  - BACKGROUND: Skin cutaneous melanoma (SKCM) is the most common skin tumor with 
      high mortality. The unfavorable outcome of SKCM urges the discovery of prognostic 
      biomarkers for accurate therapy. The present study aimed to explore novel 
      prognosis-related signatures of SKCM and determine the significance of immune 
      cell infiltration in this pathology. METHODS: Four gene expression profiles 
      (GSE130244, GSE3189, GSE7553 and GSE46517) of SKCM and normal skin samples were 
      retrieved from the GEO database. Differentially expressed genes (DEGs) were then 
      screened, and the feature genes were identified by the LASSO regression and 
      Boruta algorithm. Survival analysis was performed to filter the potential 
      prognostic signature, and GEPIA was used for preliminary validation. The area 
      under the receiver operating characteristic curve (AUC) was obtained to evaluate 
      discriminatory ability. The Gene Set Variation Analysis (GSVA) was performed, and 
      the composition of the immune cell infiltration in SKCM was estimated using 
      CIBERSORT. At last, paraffin-embedded specimens of primary SKCM and normal skin 
      tissues were collected, and the signature was validated by fluorescence in situ 
      hybridization (FISH) and immunohistochemistry (IHC). RESULTS: Totally 823 DEGs 
      and 16 feature genes were screened. IFI16 was identified as the signature 
      associated with overall survival of SKCM with a great discriminatory ability 
      (AUC > 0.9 for all datasets). GSVA noticed that IFI16 might be involved in 
      apoptosis and ultraviolet response in SKCM, and immune cell infiltration of IFI16 
      was evaluated. At last, FISH and IHC both validated the differential expression 
      of IFI16 in SKCM. CONCLUSIONS: In conclusion, our comprehensive analysis 
      identified IFI16 as a signature associated with overall survival and immune 
      infiltration of SKCM, which may play a critical role in the occurrence and 
      development of SKCM.
CI  - (c) 2021. The Author(s).
FAU - Wang, Hanwen
AU  - Wang H
AD  - Department of Burn Surgery, The First Affiliated Hospital of Sun Yat-Sen 
      University, Guangzhou, 510080, Guangdong, People's Republic of China.
FAU - Xie, Xiaoxia
AU  - Xie X
AD  - Department of Burn Surgery, The First Affiliated Hospital of Sun Yat-Sen 
      University, Guangzhou, 510080, Guangdong, People's Republic of China.
FAU - Zhu, Junyou
AU  - Zhu J
AD  - Department of Burn Surgery, The First Affiliated Hospital of Sun Yat-Sen 
      University, Guangzhou, 510080, Guangdong, People's Republic of China.
FAU - Qi, Shaohai
AU  - Qi S
AD  - Department of Burn Surgery, The First Affiliated Hospital of Sun Yat-Sen 
      University, Guangzhou, 510080, Guangdong, People's Republic of China. 
      qishaohaigzburns@163.com.
FAU - Xie, Julin
AU  - Xie J
AUID- ORCID: 0000-0002-0076-038X
AD  - Department of Burn Surgery, The First Affiliated Hospital of Sun Yat-Sen 
      University, Guangzhou, 510080, Guangdong, People's Republic of China. 
      xiejulin@mail.sysu.edu.cn.
LA  - eng
GR  - 81871566/National Natural Science Foundation of China/
GR  - 82072178/National Natural Science Foundation of China/
PT  - Journal Article
DEP - 20211220
PL  - England
TA  - Cancer Cell Int
JT  - Cancer cell international
JID - 101139795
PMC - PMC8690488
OTO - NOTNLM
OT  - Bioinformatics
OT  - Feature selection algorithm
OT  - IFI16
OT  - Prognostic signature
OT  - Skin cutaneous melanoma
COIS- The authors declare that they have no competing interests.
EDAT- 2021/12/22 06:00
MHDA- 2021/12/22 06:01
PMCR- 2021/12/20
CRDT- 2021/12/21 05:42
PHST- 2021/08/10 00:00 [received]
PHST- 2021/12/13 00:00 [accepted]
PHST- 2021/12/21 05:42 [entrez]
PHST- 2021/12/22 06:00 [pubmed]
PHST- 2021/12/22 06:01 [medline]
PHST- 2021/12/20 00:00 [pmc-release]
AID - 10.1186/s12935-021-02409-6 [pii]
AID - 2409 [pii]
AID - 10.1186/s12935-021-02409-6 [doi]
PST - epublish
SO  - Cancer Cell Int. 2021 Dec 20;21(1):694. doi: 10.1186/s12935-021-02409-6.